BioFocus DPI, the service division of Belgian drug discovery firm Galapagos, made a profit of €3.4m on revenues a little over €56m in 2008, reversing a loss of about the same magnitude in 2007.
Galapagos has bolstered the portfolio of its BioFocus DPI contract services unit by purchasing the structure-based drug discovery business of UK firm Sareum.
Galapagos' services arm has scored another lucrative contract from
big pharma - its first in the field of oncology - as it continues
to broaden its experience.
Galapagos' recent acquisitions seem to be paying off as the Belgian
biotech firm has announced its contract services unit BioFocus DPI
has inked two new deals with Japan-based Ono Pharmaceutical.